BIOCRYST PHARMACEUTICALS INC (BCRX) Corporate Subsidiaries
BIOCRYST PHARMACEUTICALS INC (BCRX) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: BCRX
CIK: 882796
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerBradley Retzlaff
Audit LocationRaleigh, North Carolina, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-09-02 | 2026-08-31 | PRIMARY DOCUMENT | 0000882796-26-000065 | View SEC Doc Filr Page |
| 4 | 2026-09-02 | 2026-08-31 | PRIMARY DOCUMENT | 0000882796-26-000063 | View SEC Doc Filr Page |
| 4 | 2026-09-02 | 2026-08-31 | PRIMARY DOCUMENT | 0000882796-26-000061 | View SEC Doc Filr Page |
| 4 | 2026-09-02 | 2026-08-31 | PRIMARY DOCUMENT | 0000882796-26-000059 | View SEC Doc Filr Page |
| 4 | 2026-09-02 | 2026-08-31 | PRIMARY DOCUMENT | 0000882796-26-000057 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001231919-26-000919 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-07 | — | SCHEDULE 13G Filing | 0000093751-26-000420 | View SEC Doc Filr Page |
| S-8 | 2026-08-05 | — | FORM S-8 | 0001171843-26-005245 | View SEC Doc Filr Page |
| 10-Q | 2026-08-05 | 2026-06-30 | 10-Q | 0001628280-26-053300 | View SEC Doc Filr Page |
| 8-K | 2026-08-05 | 2026-08-05 | FORM 8-K | 0001171843-26-005223 | View SEC Doc Filr Page |
| 8-K/A | 2026-08-04 | 2026-06-25 | FORM 8-K/A | 0001171843-26-005168 | View SEC Doc Filr Page |
| 8-K | 2026-06-29 | 2026-06-25 | FORM 8-K | 0001171843-26-004333 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000055 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000053 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000052 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000045 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000043 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000041 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000039 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000037 | View SEC Doc Filr Page |
| 4 | 2026-06-15 | 2026-06-11 | PRIMARY DOCUMENT | 0000882796-26-000035 | View SEC Doc Filr Page |
| 8-K | 2026-06-12 | 2026-06-11 | FORM 8-K | 0001171843-26-004096 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-05-29 | PRIMARY DOCUMENT | 0000882796-26-000033 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-05-29 | PRIMARY DOCUMENT | 0000882796-26-000031 | View SEC Doc Filr Page |
| 4 | 2026-06-02 | 2026-05-29 | PRIMARY DOCUMENT | 0000882796-26-000029 | View SEC Doc Filr Page |